Abstract
The anticancer properties of histone deacetylase inhibitors have been known for some time. However, it is only recently that the functional identities of the intracellular targets mediating the anticancer properties have started to be revealed. These targets appear to play significant roles in cell cycle control, apoptosis and differentiation. Importantly, the modulation of these activities is likely to be mediated by alterations in the acetylation status of both histone and non-histone targets. Identification of these targets, and the specific histone deacetylase enzymes that modulate them, is an important step in designing rationalbased therapies for the treatment of cancer. In this review we discuss the state of progress in identifying the molecular pathways / events mediating the anticancer activity of histone deacetylase inhibitors.
Keywords: Molecular Targets, anticancer properties, non-histone targets, ACETYLATION, TRANSCRIPTIONAL REGULATION, HDAC Inhibitors, Histone deacetylase enzymes, Retinoic acid, Suberoylanilide hydroxamic acid, Trichostatin A
Current Cancer Drug Targets
Title: Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Volume: 2 Issue: 4
Author(s): B. G. Gabrielli, R. W. Johnstone and N. A. Saunders
Affiliation:
Keywords: Molecular Targets, anticancer properties, non-histone targets, ACETYLATION, TRANSCRIPTIONAL REGULATION, HDAC Inhibitors, Histone deacetylase enzymes, Retinoic acid, Suberoylanilide hydroxamic acid, Trichostatin A
Abstract: The anticancer properties of histone deacetylase inhibitors have been known for some time. However, it is only recently that the functional identities of the intracellular targets mediating the anticancer properties have started to be revealed. These targets appear to play significant roles in cell cycle control, apoptosis and differentiation. Importantly, the modulation of these activities is likely to be mediated by alterations in the acetylation status of both histone and non-histone targets. Identification of these targets, and the specific histone deacetylase enzymes that modulate them, is an important step in designing rationalbased therapies for the treatment of cancer. In this review we discuss the state of progress in identifying the molecular pathways / events mediating the anticancer activity of histone deacetylase inhibitors.
Export Options
About this article
Cite this article as:
Gabrielli G. B., Johnstone W. R. and Saunders A. N., Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress, Current Cancer Drug Targets 2002; 2 (4) . https://dx.doi.org/10.2174/1568009023333818
DOI https://dx.doi.org/10.2174/1568009023333818 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine
Current Pharmacogenomics and Personalized Medicine Pertinence of Apoptosis Markers for the Improvement of In Vitro Fertilization (IVF)
Current Medicinal Chemistry Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Concise Synthesis of Benzoindolizidine Derivatives and Bioactivity Evaluation
Letters in Organic Chemistry Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
Current Cancer Drug Targets Advances in DNA-Ligands with Groove Binding, Intercalating and/or Alkylating Activity: Chemistry, DNA-Binding and Biology
Current Medicinal Chemistry Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology Cellomics as Integrative Omics for Cancer
Current Proteomics Cytotoxic and Antitumoral Activity of N-(9H-purin-6-yl) Benzamide Derivatives and Related Water-soluble Prodrugs
Current Molecular Pharmacology Notch-Associated MicroRNAs in Cancer
Current Drug Targets Novel Immunotherapeutic Strategies for Invasive Fungal Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Bio-AIMS Collection of Chemoinformatics Web Tools based on Molecular Graph Information and Artificial Intelligence Models
Combinatorial Chemistry & High Throughput Screening Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Breast Cancer, a Stem Cell Disease
Current Stem Cell Research & Therapy Folate-conjugated Chitosan-poly(ethylenimine) Copolymer As An Efficient and Safe Vector For Gene Delivery in Cancer Cells
Current Gene Therapy